Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ALN-TTRSC02 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| ALN-TTRSC02 | ACTIVE_COMPARATOR | - |
| Sterile normal saline 0.9% for SC administration | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| ALN-TTRSC02 | DRUG | Ascending doses of ALN-TTRSC02 by subcutaneous (SC) injection |
| Sterile Normal Saline (0.9% NaCl) | DRUG | Calculated volume to match active comparator |
Inclusion Criteria: * Male and female subjects, age 18 to 65 years, inclusive. * Body mass index (BMI) ≥18.0 kg/m2 and ≤30 kg/m2 assessed at Screening. * No clinically significant health concerns, as determined by medical history and physical examination, in the opinion of the Investigator. * Women...
ALN-TTRSC is an investigational drug being developed for transthyretin-mediated amyloidosis (ATTR amyloidosis), a rare disease. It is currently in Phase 1 clinical development. The drug is being studied in healthy volunteers to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics.
ALN-TTRSC is being developed by Alnylam Pharmaceuticals, Inc., a biopharmaceutical company. The company's stock ticker is ALNY. The drug is currently in Phase 1 clinical trials for transthyretin-mediated amyloidosis.
ALN-TTRSC is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The drug is being studied in healthy volunteers to assess its safety and tolerability.
ALN-TTRSC has been studied in three completed Phase 1 clinical trials. These include NCT01814839, NCT02797847, and NCT05661916. All trials were conducted in the United Kingdom and enrolled healthy volunteers aged 18 years and older.
ALN-TTRSC is also known as revusiran. In clinical trial NCT01814839, the drug is referred to as ALN-TTRSC (Revusiran). The drug is being developed for transthyretin-mediated amyloidosis.